|
|
Blood, 15 December 2003, Vol. 102, No. 13, pp. 4535-4540.
Prepublished online as a Blood First Edition Paper on August 14, 2003; DOI 10.1182/blood-2003-03-0870.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity
Judy Tellam,
Geoff Connolly,
Natasha Webb,
Jaikumar Duraiswamy, and
Rajiv Khanna
From the Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Australia; and Department of Molecular and Cellular Pathology, University of Queensland, Brisbane, Australia.
The ability of viral or mutated cellular oncogenes to initiate neoplastic events and their poor immunogenicity have considerably undermined their potential use as immunotherapeutic tools for the treatment of human cancers. Using an Epstein-Barr virus-encoded oncogene, latent membrane protein 1 (LMP1), as a model, we report a novel strategy that both deactivates cellular signaling pathways associated with the oncogenic phenotype and reverses poor immunogenicity. We show that cotranslational ubiquitination combined with N-end rule targeting of LMP1 enhanced the intracellular degradation of LMP1 and total blockade of LMP1-mediated nuclear factor- B (NF- B) and signal transducer and activator of transcription (STAT) activation in human cells. In addition, although murine cells expressing LMP1 were uniformly tumorigenic, this oncogenicity was completely abrogated by covalent linkage of LMP1 with ubiquitin, while an enhanced CD8+ T cell response to a model epitope fused to the C-terminus of LMP1 was observed following immunization with ubiquitinated LMP1. These observations suggest that proteasomal targeting of tumor-associated oncogenes could be exploited therapeutically by either gene therapy or vaccination. (Blood. 2003;102:4535-4540)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Smith, L. Beagley, and R. Khanna
Acquisition of Polyfunctionality by Epstein-Barr Virus-Specific CD8+ T Cells Correlates with Increased Resistance to Galectin-1-Mediated Suppression
J. Virol.,
June 15, 2009;
83(12):
6192 - 6198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Pandya and D. M. Walling
Oncogenic Activity of Epstein-Barr Virus Latent Membrane Protein 1 (LMP-1) Is Down-Regulated by Lytic LMP-1.
J. Virol.,
August 1, 2006;
80(16):
8038 - 8046.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Delmas, L. Martin, M. Baron, J. A. Nelson, D. N. Streblow, and J.-L. Davignon
Optimization of CD4+ T Lymphocyte Response to Human Cytomegalovirus Nuclear IE1 Protein through Modifications of Both Size and Cellular Localization
J. Immunol.,
November 15, 2005;
175(10):
6812 - 6819.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|